Immuneering (NASDAQ:IMRX – Get Free Report) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect Immuneering to post earnings of ($0.29) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 PM ET.
Immuneering (NASDAQ:IMRX – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). On average, analysts expect Immuneering to post ($1.19) EPS for the current fiscal year and ($1.58) EPS for the next fiscal year.
Immuneering Trading Down 0.8%
NASDAQ:IMRX opened at $3.65 on Tuesday. The firm has a market cap of $236.37 million, a price-to-earnings ratio of -3.54 and a beta of 0.49. The company’s 50-day moving average is $4.09 and its two-hundred day moving average is $4.77. Immuneering has a 12-month low of $3.35 and a 12-month high of $8.48.
Wall Street Analyst Weigh In
Get Our Latest Analysis on IMRX
About Immuneering
Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.
Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.
See Also
- Five stocks we like better than Immuneering
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
